利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.032 秒)

    Biomaker for ovarian and endometrial cancer: hepcidin
    1.
    发明申请
    Biomaker for ovarian and endometrial cancer: hepcidin 审中-公开
    卵巢和子宫内膜癌的生物制剂：铁调素

    公开(公告)号：US20100068724A1

    公开(公告)日：2010-03-18

    申请号：US12381218

    申请日：2009-03-09

    申请人： Eric T. Fung ,  Robert Bast ,  Daniel W. Chan ,  Jin Song ,  Valdimir Podust ,  Zhen Zhang

    发明人： Eric T. Fung ,  Robert Bast ,  Daniel W. Chan ,  Jin Song ,  Valdimir Podust ,  Zhen Zhang

    IPC分类号： G01N33/53 ,  G01N33/543

    CPC分类号： G01N33/6851 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/68 ,  G01N33/74 ,  G01N2500/00

    摘要： The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译： 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地，已经发现，铁调素是卵巢癌和子宫内膜癌的生物标志物，并且一组生物标志物，包括铁调素，转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。

    Biomarker for ovarian and endometrial cancer: hepcidin
    2.
    发明授权
    Biomarker for ovarian and endometrial cancer: hepcidin 有权
    卵巢和子宫内膜癌的生物标记物：铁调素

    公开(公告)号：US07510842B2

    公开(公告)日：2009-03-31

    申请号：US11373833

    申请日：2006-03-10

    申请人： Valdimir Podust ,  Zhen Zhang ,  Eric T. Fung ,  Robert Bast ,  Daniel W. Chan ,  Jin Song

    发明人： Valdimir Podust ,  Zhen Zhang ,  Eric T. Fung ,  Robert Bast ,  Daniel W. Chan ,  Jin Song

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6851 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/68 ,  G01N33/74 ,  G01N2500/00

    摘要： The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

    摘要翻译： 本发明提供了可用于鉴定卵巢癌状态以及患者中子宫内膜癌状态的基于蛋白质的生物标志物和生物标志物组合。 特别地，已经发现，铁调素是卵巢癌和子宫内膜癌的生物标志物，并且一组生物标志物，包括铁调素，转甲状腺素蛋白和任选的其他标记物可用于将受试者样品分类为卵巢癌或非卵巢癌。 生物标志物可以通过SELDI质谱检测。

    BIOMARKERS FOR PERIPHERAL ARTERY DISEASE
    9.
    发明申请
    BIOMARKERS FOR PERIPHERAL ARTERY DISEASE 审中-公开
    外周动脉疾病的生物标志物

    公开(公告)号：US20110313681A1

    公开(公告)日：2011-12-22

    申请号：US13218012

    申请日：2011-08-25

    申请人： Eric T. Fung ,  John P. Cooke ,  Xiao-Ying Meng ,  Tai-Tung Yip ,  Fujan Zhang

    发明人： Eric T. Fung ,  John P. Cooke ,  Xiao-Ying Meng ,  Tai-Tung Yip ,  Fujan Zhang

    IPC分类号： G06F19/00 ,  C07K14/435 ,  C07K16/18 ,  C07K14/76

    CPC分类号： G01N33/6893 ,  G01N2800/32 ,  G01N2800/324

    摘要： This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

    摘要翻译： 本发明提供了血浆中的浓度与患有血浆样品的患者中存在或不存在PAD有关的生物标志物。 本发明还提供用于区分长跛行者的PAD患者和不是PAD患者的生物标志物。 此外，本发明提供了用于鉴定另外的生物标志物的方法，用于检测患者中生物标志物的方法，以及用于鉴定与生物标志物相互作用并可用于预防或治疗患者中PAD的药剂（包括药剂）的方法。